Drugs / TAS0612
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04586270 | Oct 2020 → Nov 2024 | — | Taiho Oncology, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS0612 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04586270 ↗ |
| Modality | Small molecule | — CHEMBL4650277 ↗ |
| Route | Oral | “TAS0612 administered orally” NCT04586270 ↗ |